Bianchi Porro G, Petrillo M, Ardizzone S
Gastrointestinal Unit, L. Sacco Hospital, Milan, Italy.
J Int Med Res. 1989 Jul-Aug;17(4):320-3. doi: 10.1177/030006058901700403.
A double-blind, double-dummy controlled study to compare the clinical efficacy and gastric tolerability of salsalate and piroxicam in the treatment of rheumatoid arthritis was performed. A total of 23 patients were treated with 1.5 g salsalate twice daily and 20 with 20 mg piroxicam (after the evening meal) for 4 weeks. Patients were submitted to gastroscopy at the start and end of treatment; only patients who presented a normal baseline gastroscopy were admitted to the trial. At the end of the planned treatment period, a statistically significant improvement of all clinical variables was observed in both treatment groups, the difference between the two drugs not being statistically significant. Five of 20 (25%) piroxicam treated patients and only 2/19 (11%) salsalate treated patients showed gastric lesions at final endoscopy. No relationship was found between dyspeptic symptoms and endoscopic lesions. The results show that salsalate and piroxicam have equal efficacy in relieving arthritic symptoms, but salsalate causes fewer gastric lesions.
开展了一项双盲、双模拟对照研究，以比较水杨酸盐和吡罗昔康治疗类风湿性关节炎的临床疗效及对胃的耐受性。共有23例患者每日两次服用1.5 g水杨酸盐，20例患者（晚餐后）服用20 mg吡罗昔康，疗程4周。治疗开始和结束时对患者进行胃镜检查；仅纳入基线胃镜检查正常的患者进行试验。在计划治疗期结束时，两个治疗组的所有临床变量均有统计学意义的改善，两种药物之间的差异无统计学意义。20例接受吡罗昔康治疗的患者中有5例（25%）在末次内镜检查时出现胃部病变，而接受水杨酸盐治疗的患者中只有2/19（11%）出现胃部病变。未发现消化不良症状与内镜下病变之间存在关联。结果表明，水杨酸盐和吡罗昔康在缓解关节炎症状方面疗效相当，但水杨酸盐引起的胃部病变较少。
